Wolfgang Fischl
Chief Executive Officer YGION Biomedical
Wolfgang Fischl is co-founder and CEO of YGION Biomedical, a Vienna-based clinical-stage biotechnology company developing personalized neoantigen immunotherapies for aggressive solid tumors.
Seminars
Thursday 3rd December 2026
Personalized Neoantigen Peptide Immunotherapy in Glioblastoma: From Pre-screening to Clinical Phase 1
12:30 pm
- Pre-screening in glioblastoma – Identifying patients with sufficient tumor material and actionable neoantigen profiles for a personalized, targeted peptide-based immunotherapy
- Mechanistic basis and immune readouts – A targeted peptide-based approach designed to prime neoantigen-specific T-cell responses, with immune monitoring assays to capture activation, breadth, and durability
- Pathways to scalability – Identifying key drivers such as prediction accuracy, manufacturing performance, and workflow coordination that will enable future scaling of personalized peptide-based programs
